PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY

• Main Authors: Ekaterina I. Alexeeva (Author), Tatyana M. Dvoryakovskaya (Author), Kseniya B. Isaeva (Author), Tatyana V. Sleptsova (Author), Rina V. Denisova (Author), Margarita A. Soloshenko (Author), Olga L. Lomakina (Author), Anna N. Fetisova (Author), Mariya G. Rudnickaya (Author), Dariya D. Vankova (Author), Alina A. Alshevskaya (Author), Andrei V. Moskalev (Author), Anna V. Mamutova (Author)
• Format: Book
• Published: "Paediatrician" Publishers LLC, 2018-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background. To assign genetically engineered biologic drugs, we need data on the predictors for response to therapy. Prognostic factors for the response to tocilizumab in patients with juvenile idiopathic arthritis (JIA) without systemic symptoms are poorly studied.Objective. Our aim was to reveal e...